| Project/Area Number |
17K11119
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
米山 徹 弘前大学, 医学研究科, 助教 (50587649)
石山 新太郎 弘前大学, 理工学研究科, 教授 (60355021)
飛澤 悠葵 弘前大学, 医学研究科, 助教 (70623768)
大山 力 弘前大学, 医学研究科, 教授 (80282135)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 中性子補足療法 / 糖鎖生物学 / がん化学療法 / 手術療法 / 癌特異的中性子補足療法 / ペプチド / がん特異的中性子治療 / 腫瘍血管内皮細胞 / 分子標的治療 |
|---|
| Outline of Final Research Achievements |
We developed a tumor-targeting Boron neutron capture therapy (BNCT) using tumor vasculature endothelium targeting peptide (IF7) conjugated boronophenylalanine (BPA-IF7) to improve the biodistribution of BPA. BPA or BPA-IF7 (7 mg/kg, 1/35 of effective dose) was intravenously administrated to MBT2 tumor-bearing mice. The tumors received reactor thermal neutron beam irradiation following the administration of 7 mg/kg of BPA-IF7. Tumor growth was compared between the irradiated (n=7) and control (n=19) mice for 2 weeks.Tumor concentration of B10 was 5-fold higher in the BPA-IF7 than that in the BPA. The tumor concentration of B10 reached 20 ppm within the 20 min in the BPA-IF7 mice. Tumor size was significantly decreased in the BPA-IF7 mice than that in the control mice. BPA-IF7 showed faster tumor-specific boron accumulation than conventional BPA and showed antitumor effects at low doses. BPA-IF7 has the potential to improve drug delivery of BPA and antitumor effect for BNCT.
|
| Academic Significance and Societal Importance of the Research Achievements |
現在の抗がん剤治療が抱える弱点は、細胞毒性の強い薬剤を全身投与する点にある。これら副作用を減らし高い抗腫瘍効果を得るためには高濃度の抗がん剤をがんのみに到達させる必要がある。我々の開発したB-IF7は、がん細胞に高濃度にホウ素を集積させることが出来るため、これら問題を解決できる可能性がある。さらに最近になって頭頚部癌に対する中性子補足療法が保険適応となったことを受け、中性子発生装置も広く普及していくものと思われ、我々の研究成果は学術的意義ならびに社会的意義の高い結果と思われる。
|
